首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >CD3 sup+/sup CD4 sup+/sup and CD3 sup+/sup CD8 sup+/sup Lymphocyte Subgroups and their Surface Receptors NKG2D and NKG2A in Patients with Non-small Cell Lung Cancer
【24h】

CD3 sup+/sup CD4 sup+/sup and CD3 sup+/sup CD8 sup+/sup Lymphocyte Subgroups and their Surface Receptors NKG2D and NKG2A in Patients with Non-small Cell Lung Cancer

机译:CD3 + / sup> cd4 + 和cd3 + cd8 + 淋巴细胞亚组及其表面受体nkg2d和nkg2a,nkg2d和nkg2a在非-Small细胞肺癌

获取原文
           

摘要

To explore the prevalence of lymphocyte subgroups CD3+ CD4+ and CD3+ CD8+ and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer (NSCLC). A total of 40 patients with NSCLC were divided into different groups according to different clinical factors (TNM staging, pathological patterns and genders) for assessment of relations with CD3+ CD4+ and CD3+ CD8+ and the surface receptors NKG2D and NKG2A of T lymphocytes in peripheral blood by flow cytometry. Patients in the advanced group had evidently lower levels of CD3+ CD4+ but markedly higher levels of CD3+ CD8+ in peripheral blood than those with early lesions (p0.05). In addition, NSCLC patients in the advanced group had obviously higher CD3+ CD4+ NKG2D and CD3+ CD8+ NKG2A expression rates but lower CD3+ CD4+ NKG2A and CD3+ CD8+ NKG2D expression rates (p0.05). However, there were no significant differences between NSCLC patients with different genders and pathological patterns in expression levels of lymphocyte subgroups CD3+ CD4+ and CD3+ CD8+ and their surface receptors NKG2D and NKG2A. Unbalanced expression of surface receptors NKG2D and NKG2A in CD3+ CD4+ and CD3+ CD8+ lymphocytes may be associated with a poor prognosis, greater malignancy and immunological evasion by advanced cancers, related to progression of lung cancer.
机译:为了探讨淋巴细胞亚组CD3 + CD4 +和CD3 + CD8 +及其表面受体NKG2D和NKG2A的患病率为非小细胞肺癌(NSCLC)。根据不同的临床因素(TNM分期,病理模式和性别),共分为40例NSCLC患者,用于评估与CD3 + CD4 +和CD3 + CD8 +和表面受体NKG2D和外周血T淋巴细胞的NKG2A的关系流式细胞术。晚期患者在外周血中显着降低了CD3 + CD4 +但明显高度的CD3 + CD8 +水平,而不是早期病变(P <0.05)。此外,先进组的NSCLC患者明显高达CD3 + CD4 + NKG2D和CD3 + CD8 + NKG2A表达率,但下降CD3 + CD4 + NKG2A和CD3 + CD8 + NKG2D表达率(P <0.05)。然而,NMSCLC患者在淋巴细胞亚组CD3 + CD4 +和CD3 + CD8 +和其表面受体NKG2D和NKG2A的表达水平中没有不同的性别和病理模式之间没有显着差异。表面受体NKG2D和NKG2a在CD3 + CD4 +和CD3 + CD8 +淋巴细胞中的不平衡表达可能与晚期预后,晚期癌症的更高,恶性肿瘤和免疫疏散有关,与肺癌的进展相关。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号